Matthew Tobin, MD
Urology · Neptune, NJNPI 1366425332
Payments from drug & device makers
Across 102 payments — averaging $20.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Antares Pharma, Inc.$391
- Medtronic$212
- Calyxo, Inc.$204
- Myovant Sciences Inc.$125
- Astellas Pharma US Inc$115
- Coloplast$99
- plus $950 from 30 others
What the payments were for
- Food & beverage$2,02096%
- Education$754%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Antares Pharma, Inc. | 24 | $391 |
| Medtronic(2 entities) | 3 | $212 |
| Calyxo, Inc. | 3 | $204 |
| Myovant Sciences Inc. | 4 | $125 |
| Astellas Pharma US Inc | 4 | $115 |
| Coloplast | 6 | $99 |
| Dentsply IH AB | 3 | $75 |
| Axonics, Inc. | 4 | $71 |
| AbbVie(2 entities) | 5 | $69 |
| Boston Scientific | 2 | $59 |
| Johnson & Johnson | 4 | $57 |
| Teleflex LLC | 4 | $56 |
| Olympus America Inc. | 2 | $52 |
| Urogen Pharma, Inc. | 3 | $45 |
| Bayer | 2 | $38 |
| Accord Healthcare, Inc. | 2 | $29 |
| Progenics Pharmaceuticals, Inc. | 2 | $29 |
| Blue Earth Diagnostics | 1 | $28 |
| 180 Medical, Inc. | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Acerus Pharmaceuticals Corporation | 2 | $26 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $26 |
| Tolmar Pharmaceuticals, Inc. | 2 | $24 |
| Avadel Specialty Pharmaceuticals, LLC | 2 | $23 |
| Bioprotect Medical, Inc. | 1 | $20 |
| Clarus Therapeutics Inc. | 2 | $19 |
| Dentsply IH Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
| Laborie Medical Technologies Corp. | 1 | $15 |
| Telix Pharmaceuticals | 1 | $15 |
| Merck | 1 | $15 |
| Aytu Biopharma, Inc. | 1 | $14 |
| Photocure Inc | 1 | $14 |
| Tolmar, Inc. | 1 | $13 |
| Neotract Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CVAC Aspiration System$140
- INTERSTIM$106
How this compares
$2,095 in reported general payments places this provider in the 45th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 130 | $111,314 |
| Tamsulosin Hcl | 1,454 | $26,210 |
| Finasteride | 1,318 | $21,449 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 68 | $18,612 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 526 | $14,433 |
| Silodosin | 101 | $10,576 |
| Dutasteride | 172 | $7,063 |
| Potassium Citrate ErPotassium Citrate | 18 | $3,063 |
| Oxybutynin Chloride ErOxybutynin Chloride | 75 | $2,509 |
| Solifenacin Succinate | 42 | $2,289 |
| Testosterone | 32 | $2,137 |
| Methenamine Hippurate | 20 | $1,809 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 275 | $1,565 |
| Doxazosin Mesylate | 84 | $1,351 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $1,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $115 | $111,314130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 401 urology providers in New Jersey.
Other urology in Neptune
- Gordon BrownCherry Hill$2.8M
- Nitin YerramHackensack$1.6M
- Michael StifelmanHackensack$1.5M
- Thomas MuellerLinwood$1.2M
- David SussmanLinwood$833K
- Michael IngberDenville$607K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$464K
- Neil ShermanCranford$404K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.